Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal Origin

BMC Cancer

Research Article

Joerg OW Pelz¹  Joerg Doerfer¹  Alexander G Kerscher¹  Uwe Maeder¹  Christoph-Thomas Germer¹  Alexander Stojadinovic²  Jesus Esquivel³  Terence C Chua⁴  David L Morris⁴ 

[1] Department of General-, Visceral-, and Paediatric Surgery, University of Wuerzburg, Germany;Department of Surgery, Walter Reed Army Medical Center and the United States Military Cancer Institute, Washington, USA;Department of Surgical Oncology, St. Agnes Hospital, Baltimore, MD, USA;UNSW Department of Surgery, St George Hospital, Sydney, NSW, Australia;

关键词: Systemic Chemotherapy;    Metastatic Colorectal Cancer;    Peritoneal Carcinomatosis;    Cytoreductive Surgery;    Complete Cytoreduction;   

DOI  :  10.1186/1471-2407-10-689

 received in 2010-02-09, accepted in 2010-12-22,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundWe evaluate the long-term survival of patients with peritoneal carcinomatosis (PC) treated with systemic chemotherapy regimens, and the impact of the of the retrospective peritoneal disease severity score (PSDSS) on outcomes.MethodsOne hundred sixty-seven consecutive patients treated with PC from colorectal cancer between years 1987-2006 were identified from a prospective institutional database. These patients either received no chemotherapy, 5-FU/Leucovorin or Oxaliplatin/Irinotecan-based chemotherapy. Stratification was made according to the retrospective PSDSS that classifies PC patients based on clinically relevant factors. Survival analysis was performed using the Kaplan-Meier method and comparison with the log-rank test.ResultsMedian survival was 5 months (95% CI, 3-7 months) for patients who had no chemotherapy, 11 months (95% CI, 6-9 months) for patients treated with 5 FU/LV, and 12 months (95% CI, 4-20 months) for patients treated with Oxaliplatin/Irinotecan-based chemotherapy. Survival differed between patients treated with chemotherapy compared to those patients who did not receive chemotherapy (p = 0.026). PSDSS staging was identified as an independent predictor for survival on multivariate analysis [RR 2.8 (95%CI 1.5-5.4); p < 0.001].ConclusionA trend towards improved outcomes is demonstrated from treatment of patients with PC from colorectal cancer using modern systemic chemotherapy. The PSDSS appears to be a useful tool in patient selection and prognostication in PC of colorectal origin.

【 授权许可】

CC BY   
© Pelz et al; licensee BioMed Central Ltd. 2010